Pfizer Covid-19 vaccine meets safety milestone, will submit for EUA

Share

Drugmaker Pfizer Inc "didn't conspire with anyone" to delay releasing efficacy results for the COVID-19 vaccine it developed with German partner BioNTech SE until after the US presidential election, Chief Executive Albert Bourla said at a New York Times conference on Tuesday.

The vaccine has been developed with breathtaking speed - just 10 months after the genetic code of the novel coronavirus was first sequenced - and a completed study of trials showed it was 95 percent effective in protecting people from infection.

It also includes solicited safety data on approximately 100 children aged between 12 and 15 years.

Calif. hospitals 'crushed' by virus
The latest explosion of cases has been tied to people ignoring social-distancing rules during the Thanksgiving holiday. Entertainment production - including professional sports - would be allowed to continue without live audiences.

"Here in the United Kingdom, the first step for authorising a vaccine is for the government formally to ask the independent regulator..., the MHRA, to assess its suitability", Hancock told reporters.

Based on current projections, the companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021.

"We look forward to the upcoming Vaccines and Related Biological Products Advisory Committee discussion and continue to work closely with the FDA and regulatory authorities worldwide to secure authorization of our vaccine candidate as quickly as possible".

Share